MIRA Pharmaceuticals Initiates Phase 1 Study of Ketamir-2 for Neuropathic Pain

MIRA Pharmaceuticals has commenced the multiple ascending dose (MAD) phase of its Phase 1 clinical trial for Ketamir-2, targeting chemotherapy-induced peripheral neuropathy (CIPN). This follows the completion of the single ascending dose (SAD) phase where no serious adverse events were recorded. The ongoing study aims to assess safety and pharmacokinetics of Ketamir-2 across multiple dosing levels.

Preclinical data highlights Ketamir-2's promise in neuropathic pain management, outperforming existing treatments like gabapentin and pregabalin. The drug's design offers good oral absorption, avoids hallucinogenic effects, and supports once-daily dosing. MIRA anticipates potential FDA Fast Track designation, enhancing its market opportunities.